The medication is applied across therapeutic domains involving inflammatory states of the respiratory and ENT tracts, supporting the management of key symptomatic clusters. It is commonly used in conditions presenting with significant inflammatory symptoms, such as acute laryngitis, chronic bronchitis, tracheobronchitis, rhinopharyngitis, otitis, and as adjunct support for asthma.

The primary benefit is related to helping moderate the overall intensity of symptoms associated with pronounced irritation and swelling, and assists in addressing symptoms related to inflammatory or irritative states. This offers supportive relief when symptoms cluster around a persistent, pathological cough and excessive sputum production, which may help patients cope more steadily with difficult episodes. The medication is also relevant in clinical settings where temporary functional strain, such as bronchial tightness or restricted breathing, is present, as it contributes to easing the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

“The therapeutic focus is on easing symptomatic burden in conditions where inflammation and functional airway strain occur together.”

---

Quick Fact: Focus on Inflammatory Symptom Management

Эриспирус is commonly used for managing symptoms related to both airway irritation and cough/secretion, particularly in scenarios requiring temporary assistance in symptom stabilization.

Who can and cannot use Эриспирус? (Fenspiride Hydrochloride)

Official regulatory information defines the eligibility profile for Эриспирус as one of universal non-eligibility in regions subject to the European Medicines Agency (EMA) review.

Eligibility Scope

Criteria	Official Regulatory Status
Populations for whom use is allowed	None. Marketing authorizations have been revoked by regulatory authorities due to safety concerns, establishing a universal prohibition on use.
Populations for whom use is contraindicated	All patients are strictly contraindicated due to the confirmed, unpredictable risk of serious heart rhythm problems (QT prolongation and Torsades de Pointes).
Hypersensitivity	Individuals with known hypersensitivity to Fenspiride hydrochloride or its excipients are contraindicated.
Age-related eligibility rules	Contraindicated in children below 2 years of age, according to prior labeling.

Eligibility Classifications

The primary eligibility classification is Absolute Contraindication and Revocation of Marketing Authorization by regulatory bodies, including the EMA. This decision is based on the drug's confirmed proarrhythmia potential, meaning it must not be used by any patient due to the overriding cardiac safety concern.

Interactions with other medicines and products

This section describes officially documented interaction patterns for the active ingredient, Fenspiride hydrochloride, as outlined in governmental regulatory documents.

Formal Interaction Restrictions

The product's official interaction profile is structured around two primary pharmacodynamic domains that necessitate restrictions on co-administration.

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Severe Pharmacodynamic	Medicinal products known to prolong the QT interval	Co-administration is formally restricted due to the documented risk of QT interval prolongation, which may lead to life-threatening ventricular arrhythmias, as cited in regulatory assessments.
Pharmacodynamic	Medicinal products possessing a sedative effect	Co-administration is not recommended due to the potential for an enhanced sedative effect.
Drug–Substance	Alcohol (Ethanol)	Concurrent consumption is restricted due to the potential for enhancement of the sedative effect.

Other Interaction Context

Official regulatory documentation contains no explicit statements regarding specific pharmacokinetic interactions, such as those mediated by CYP enzymes, nor does it mandate specific timing requirements (e.g., separating administration by a defined number of hours) for any co-administered substance. Furthermore, no population-specific interaction considerations, such as altered severity in patients with hepatic impairment, are documented in the official prescribing information.

How Эриспирус Works: Mechanism of Action

The mechanism of action for Эриспирус (Fenspiride hydrochloride) is based on a multi-target approach that influences the biological processes governing inflammation, smooth muscle contraction, and glandular output.

---

Dual Modulation of Inflammatory and Spasm Signals

The molecule acts by both antagonizing Histamine H1 receptors and inhibiting specific Phosphodiesterase ( PDE) enzymes, particularly PDE4 and PDE3. This dual mechanism influences the production of key mediators like histamine, leukotrienes, and certain cytokines, while also increasing intracellular levels of cAMP. The resulting physiological effect is a modulation of cell function and a suppression of signaling by specific chemical mediators.

---

Control Over Airway Tone and Secretion

The drug's mechanism extends to smooth muscle cells and glandular tissue, where it causes functional relaxation and reduced fluid output. By blocking H1 and alpha1-adrenergic receptors, the drug directly prevents signals that cause excessive muscle contraction and stimulate the secretion of mucus. This effect contributes to modulating smooth muscle tone and adjusting the glandular output in the respiratory lining.

Official Administration Guidelines and Regulatory Status

Эриспирус (Fenspiride hydrochloride) was administered via the oral route and was historically available in both tablet and syrup dosage forms. The current status of this medicine is defined by regulatory action.

Administration Scope

Parameter	Instruction
Route of administration	Oral for systemic effect.
Dosing schedule (Historical)	Adults were prescribed a total daily dose of 160 mg to 240 mg (tablets) or 45 ml to 90 ml (syrup) to be taken in divided doses.
Timing in relation to meals (Historical)	The syrup formulation was instructed to be taken directly before meals.
Age-group administration rules (Historical)	Pediatric dosage for children aged 2 years was determined by body weight at 4 mg/kg per day.
Current Procedural Condition	Cessation of Use: Marketing authorizations for fenspiride-containing medicines have been revoked; prescribing and taking the medicine should be discontinued.

Resulting Procedural Structure

The previous standard protocol was structured around administering the medicine in divided daily doses over a defined short-term period for symptomatic use. This involved the use of a measuring syringe or spoon for accurate liquid administration. This entire use protocol is now superseded by definitive regulatory instruction advising that healthcare professionals must no longer prescribe fenspiride medicines and that patients should stop taking the medicine.

Research Evidence / Overview of Studies for Эриспирус

---

Evidence for Acute Inflammatory Conditions of the Respiratory Tract and ENT

Research for Эриспирус (Fenspiride) was studied for its use in symptoms associated with inflammation in the airways and associated structures, such as acute laryngitis, tracheobronchitis, and rhinopharyngitis. The evidence base primarily involves short-term Randomized Controlled Trials (RCTs) and other clinical investigations that included adults and children. These research efforts monitored outcomes related to physical discomfort, primarily using composite clinical symptom scores to track aspects like the intensity of cough and expectoration over defined time intervals.

Studies conducted during periods of increased symptom activity reported measurements of how symptoms evolved in the observed populations during the study period. Findings described patterns observed in these short-term trials over typical follow-up periods ranging from 10 to 30 days. However, the evidence quality varies across studies, particularly in earlier research, where sample sizes were modest.

---

Evidence Landscape for Chronic Respiratory Diseases

Research has explored fenspiride through the use of preliminary Randomized Placebo-Controlled Studies and observational trials in more sustained respiratory conditions, including conditions involving periods of heightened symptoms like Chronic Obstructive Pulmonary Disease (COPD). These studies examined outcomes reflecting daily functioning or activity level and physiological strain or stress, such as measures of lung function and exercise tolerance. When evaluated in these chronic settings, data show patterns related to the use of the medication alongside standard maintenance treatments.

The evidence for this domain is limited, and certainty remains low. Comparative evidence is lacking between fenspiride and many contemporary treatments. Data are still emerging, and long-term effects are not fully established.

---

Research Gaps and Uncertainties in the Evidence

The majority of clinical research involving Эриспирус focuses on short-term symptom changes during acute periods of illness. These short-term RCTs generally utilize follow-up durations that were limited, rarely extending beyond one month. This research structure means that long-term effects are not fully established for either acute or chronic use.

Furthermore, the results apply only to the populations studied, and data for certain groups remain insufficient. For instance, evidence in groups with significant co-morbidities or specific stages of chronic disease is limited. Research does not determine whether an individual will respond similarly outside the specific conditions under which the studies were conducted.

Common questions about Эриспирус (FAQ)

---

Q: How does the action of Эриспирус compare to common antihistamines?

A: Official regulatory information describes that the active ingredient acts by blocking specific histamine receptors, a mechanism also used by antihistamines. However, the medicine also acts on specific enzymes and other receptors, giving it a dual classification. Its overall classification as an anti-inflammatory and bronchodilator indicates a scope of action that differs from typical antihistamines.

Q: Can Эриспирус be used for long-term respiratory conditions?

A: Regulatory authorities have issued a universal prohibition on the use of this medicine for all patients and all indications, including both short-term and chronic conditions. This decision was based on confirmed, unpredictable cardiac safety risks identified in official assessments. Official guidance is defined by the universal prohibition on the medicine's use for any duration, due to the overriding safety concerns.

Q: What is the maximum period of time Эриспирус is indicated for use in official documents?

A: Official regulatory instruction from government bodies advises a universal prohibition on prescribing and taking the medicine, which supersedes any prior guidance on treatment duration. The maximum period of use is defined by the current regulatory status, which is a universal prohibition on prescribing and taking the medicine.

Q: Are there alternative drugs mentioned in official sources for the conditions Эриспирус was used to treat?

A: When regulatory authorities mandated the withdrawal of the medicine, the official communication included an explicit instruction for healthcare professionals. This instruction was to ensure that professionals advised patients on alternative treatment options that could be used instead of this medicine.

Q: Can people with a history of liver problems use Эриспирус?

A: The current official guidance for the drug is a universal prohibition on use for all patients, which includes those with a history of liver problems. The universal prohibition applies to all patients, regardless of a history of other conditions, based on the overriding heart safety risks.

Q: Is there information on the safety of Эриспирус use during pregnancy?

A: Regulatory documentation previously stated that use of the active substance during pregnancy was not recommended. The safety profile for use during pregnancy, as with any medicine, should be reviewed by a health professional.

Q: Are there research studies addressing the use of Эриспирус in children?

A: Clinical investigations for the active substance have historically included studies involving children. However, prior regulatory labeling contraindicated its use in children below two years of age.

Q: If I have a history of heart issues, does the official guidance mention restrictions on using Эриспирус?

A: Yes, official guidance imposes a universal prohibition on use for all patients due to the confirmed risk of serious heart rhythm problems. Regulatory documents describe strict contraindications for individuals with risk factors for severe cardiac rhythm issues, such as a known history of QT prolongation.

Q: Does the official guidance suggest monitoring specific health parameters (e.g., heart function) during treatment with Эриспирус?

A: Regulatory authorities determined that no feasible and proportionate measures could effectively identify or monitor all patients at risk for the serious heart rhythm issues associated with the drug. This difficulty in safety assessment was a key aspect of the revocation decision.

Q: Do official patient information leaflets for Эриспирус mention precautions for people with glaucoma?

A: While the active substance is known to have certain receptor-blocking properties, glaucoma itself is typically not listed as an official contraindication in the regulatory documentation for fenspiride.

Q: Are there any documented cases of overdose with Эриспирус, and what were the symptoms?

A: Official regulatory documents describe that in cases of overdose, symptoms were observed. These included orthostatic hypotension, which is low blood pressure upon standing, and tachycardia, which is an abnormally fast heart rate.

Q: Why is the active substance in Эриспирус considered to have anti-inflammatory properties?

A: Official documents state the anti-inflammatory action is supported by the active substance’s ability to influence the production and suppress the signaling of key chemical mediators involved in the inflammatory process, such as histamine and leukotrienes.

Q: Can a patient with diabetes use Эриспирус according to official guidance?

A: The universal prohibition on use applies to all patients due to cardiac safety concerns. Prior to this, the syrup formulation contained sucrose (sugar), which required specific dietary consideration for patients with diabetes.

Q: Does Эриспирус interact with any medications used for blood pressure or heart conditions?

A: Yes, official regulatory documentation formally restricts co-administration with medicinal products known to prolong the QT interval. This category includes medicines that may be used for heart and blood pressure conditions, and co-administration is restricted due to the risk of life-threatening arrhythmias.

How to Store and Dispose of Эриспирус

Official regulatory guidelines define strict conditions for the storage and disposal of this medicine, which contains fenspiride hydrochloride.

---

Required Storage Conditions

Condition	Requirement
Temperature	Store at a temperature not exceeding 25°C (77°F).
Prohibited Storage	Do not refrigerate or freeze the product.
Packaging	Keep the medicine and its measuring device together in the original package.
Child Safety	Store the product out of the sight and reach of children.

---

Stability and Disposal

The medicine has a limited 6-month stability period after the bottle is first opened. For disposal, unused or expired product must be discarded strictly in accordance with local regulations. It is prohibited to dispose of the product by allowing it to enter drains, water courses, or the soil.